In Multiple sclerosis (MS) Multiple sclerosis (MS) is a disease of the brain and spinal cord in which a person’s own immune system attacks the protective sheath (called myelin) of the nerves. This leads to symptoms such as vision loss, pain, fatigue and improper coordination. Glatirex Injection helps to suppress the body’s immune system, thereby reducing the progression of the disease. It reduces the inflammation of the damaged nerves, prevents further damage and stabilises your immune system. This medicine is given as an injection by a doctor or nurse and should not be self-administered. Follow your doctor’s instructions carefully to get the best results.
Caution is advised when consuming alcohol with Glatirex Injection. Please consult your doctor.
Glatirex Injection is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Glatirex Injection is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
It is not known whether Glatirex Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
There is limited information available on the use of Glatirex Injection in patients with kidney disease. Please consult your doctor. Regular monitoring of kidney function tests is advised while you are taking this medicine.
There is limited information available on the use of Glatirex Injection in patients with liver disease. Please consult your doctor.
If you miss a dose of Glatirex Injection, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Cipla Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Natco Pharma Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Taj Pharma India Ltd || ₹14.5/tablet (25% cheaper)